This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Kadmon Holdings, Inc.

Drug Names(s): SLx-2101

Description: SLx-2101 is a long-acting oral PDE-5 inhibitor.

Deal Structure: In April 2011, Kadmon Pharmaceuticals and Nano Terra announced that they entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terras drug discovery platform, Pharmacomer Technology. The product candidates and technology platform will be transferred to a newly formed joint venture, NT Life Sciences (NT Life), co-owned by Kadmon and Nano Terra, which will act as the licensor and recipient of any licensing or royalty fees subject to the agreement. Terms of the agreement were not disclosed.

Partners: Nano Terra, Inc.

KD027 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug